$0.24
(22.86%)
Add to watchlist
Create an alert
Stocks and Shares ISACardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Company Information
About this company
Key people
Meeshanthini V. Dogan
Chief Executive Officer, Director
Elisa Luqman
Chief Financial Officer
Timur Dogan
Chief Technology Officer
Robert Philibert
Chief Medical Officer, Director
Warren Hosseinion
Non-Executive Chairman of the Board
Wendy J. Betts
Independent Director
Paul F. Burton
Independent Director
Peter K. Fung
Independent Director
James Intrater
Independent Director
Click to see more
Key facts
- Shares in issue1.83m
- EPICCDIO
- ISINUS14159C2026
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$2.23m
- Employees13
- ExchangeNASDAQ
- Index
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.